Protein engineering of a human enzyme that hydrolyzes V and G nerve agents: design, construction and characterization.
Because of deficiencies in the present treatments for organophosphorus anticholinesterase poisoning, we are attempting to develop a catalytic scavenger that can be administered as prophylactic protection. Currently known enzymes are inadequate for this purpose because they have weak binding and slow turnover, so we are trying to make an appropriate enzyme by protein engineering techniques. One butyrylcholinesterase mutant, G117H, has the desired type of activity but reacts much too slowly. This communication describes an attempt to determine the reason for the slow reaction so that a more efficient enzyme might be designed. The results indicate that the mutation at residue 117 has resulted in a distortion of the transition state of the reaction of organophosphorus compounds with the active site serine. This information will be used to develop other mutants that avoid transition state stabilization sites.
Broomfield
C A
CA
US Army Medical Research Institute of Chemical Defense, APG, MD 21010-5425, USA.
Lockridge
O
O
Millard
C B
CB
D000818:Animals; D001588:Benzoylcholine / Q000493:pharmacokinetics / Q000633:toxicity; D001665:Binding Sites; D002091:Butyrylcholinesterase / Q000138:chemical synthesis* / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D002092:Butyrylthiocholine / Q000493:pharmacokinetics / Q000633:toxicity; D002513:Cephamycins / Q000378:metabolism*; D002619:Chemical Warfare Agents / Q000493:pharmacokinetics* / Q000633:toxicity; D002800:Cholinesterase Inhibitors / Q000493:pharmacokinetics / Q000633:toxicity; D015195:Drug Design; D004456:Echothiophate Iodide / Q000493:pharmacokinetics / Q000633:toxicity; D006801:Humans; D006868:Hydrolysis; D008658:Inactivation, Metabolic; D007700:Kinetics; D016297:Mutagenesis, Site-Directed; D010755:Organophosphates / Q000493:pharmacokinetics / Q000633:toxicity; D009946:Organothiophosphorus Compounds / Q000378:metabolism*; D015202:Protein Engineering / Q000379:methods*; D012524:Sarin / Q000493:pharmacokinetics / Q000633:toxicity; D012999:Soman / Q000493:pharmacokinetics / Q000633:toxicity; D014101:Torpedo / Q000378:metabolism
D001588:Benzoylcholine; D002091:Butyrylcholinesterase; D002092:Butyrylthiocholine; D002513:Cephamycins; D002619:Chemical Warfare Agents; D002800:Cholinesterase Inhibitors; D004456:Echothiophate Iodide; D010755:Organophosphates; D009946:Organothiophosphorus Compounds; D012524:Sarin; D012999:Soman; C027446:oganomycins; C009680:VX-agent